Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 4 of 114

  1. 2025-521093-34-00

    Pari Pharma GmbH

    rare disease

    phase 3 small molecule active

    1 trial

  2. 2025-I2M-C&T-B-090B

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pneumocystis Jiroveci Pneumonia

    phase 3 small molecule active

    1 trial

  3. 20432A

    H. Lundbeck A/S

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  4. 206785

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  5. 207495

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  6. 207499

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. 207503

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  8. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Seizure

    phase 3 small molecule active

    1 trial

  9. 21-01/ClotriBet-S

    Alphapharm Pty Ltd

    moderate to severely inflamed candidiasis of the skin

    phase 3 small molecule active

    1 trial

  10. 21177

    Bayer AG

    Non-diabetic chronic kidney disease

    phase 3 small molecule active

    1 trial

  11. 212496

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  12. 212895

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  13. 213350/3000-03-005

    TESARO Bio Netherlands B.V.

    Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  14. 213400

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  15. 213410

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  16. 213823

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  17. 213997 (VNS 20-001)

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  18. 213998 (VNS 20-002)

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  19. 214002 (VNS 20-004)

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  20. 21466

    Bayer AG

    Heart failure due to systemic left ventricular systolic dysfunction

    phase 3 small molecule active

    1 trial

  21. 21467

    Bayer AG

    Heart failure due to systemic left ventricular systolic dysfunction

    phase 3 small molecule active

    1 trial

  22. 214828

    GlaxoSmithKline

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  23. 217013

    GlaxoSmithKline

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  24. 217102

    GlaxoSmithKline

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  25. 217848

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  26. 218224

    GlaxoSmithKline

    systemic sclerosis associated interstitial lung disease

    phase 3 small molecule active

    1 trial

  27. 219700

    ViiV Healthcare Pty Ltd

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  28. 219816

    ViiV Healthcare Pty Ltd

    Human immunodeficiency virus (HIV)

    phase 3 small molecule active

    1 trial

  29. 22-01/MPA-C

    Alphapharm Pty Ltd

    Mild to moderate atopic dermatitis

    phase 3 small molecule active

    1 trial

  30. 220030

    GlaxoSmithKline

    Invasive meningococcal disease (IMD)

    phase 3 small molecule active

    1 trial

  31. 220735

    GlaxoSmithKline

    Asthma

    phase 3 small molecule active

    1 trial

  32. 2215-CL-0201

    Astellas Pharma GmbH

    Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

    phase 3 small molecule active

    1 trial

  33. 22153

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  34. 221530

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  35. 221611

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 3 small molecule active

    1 trial

  36. 221672

    GlaxoSmithKline

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  37. 222090

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  38. 222253

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  39. 222725

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  40. 223105

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  41. 223529

    GlaxoSmithKline

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

  42. 223674

    GlaxoSmithKline

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  43. 224295

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  44. 22615

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  45. 22817

    Disc Medicine

    chronic kidney disease

    phase 3 small molecule active

    1 trial

  46. 23-01/ClindaTret-G

    Alphapharm Pty Ltd

    Papulopustular acne

    phase 3 small molecule active

    1 trial

  47. 23-03/Iver-C

    Alphapharm Pty Ltd

    Papulopustular Rosacea

    phase 3 small molecule active

    1 trial

  48. 230LE301

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.